Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
PHASE2CompletedINTERVENTIONAL
Enrollment
72
Participants
Timeline
Start Date
October 31, 2006
Primary Completion Date
June 30, 2007
Conditions
Adenosquamous Cell Lung CancerDrug/Agent Toxicity by Tissue/OrganHemoptysisSquamous Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
BIOLOGICAL
bevacizumab
Given IV
DRUG
paclitaxel
Given IV
DRUG
carboplatin
Given IV
RADIATION
radiation therapy
Undergo radiotherapy
Trial Locations (1)
Unknown
California Cancer Consortium
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00387374 - Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | Biotech Hunter | Biotech Hunter